Quarterly report pursuant to Section 13 or 15(d)

Fair Value Disclosures - Estimate to Measure Contingent Consideration Unobservable Level 3 In-process R&D (Details)

v3.24.3
Fair Value Disclosures - Estimate to Measure Contingent Consideration Unobservable Level 3 In-process R&D (Details) - Multi-Period Excess Earnings Method
Aug. 31, 2023
Probability of success for next development phase | KIO-104 | Minimum  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
In-process R&D 0.17
Probability of success for next development phase | KIO-104 | Maximum  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
In-process R&D 0.36
Probability of success for next development phase | KIO-301 | Minimum  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
In-process R&D 0.23
Probability of success for next development phase | KIO-301 | Maximum  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
In-process R&D 0.43
Payment discount rate | KIO-104  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
In-process R&D 0.43
Payment discount rate | KIO-301  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
In-process R&D 0.43